SCHEMBL4355451

SCHEMBL4355451

Cc1c(Cl)cc(NC(=S)NCCc2ccccc2)c(O)c1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.60
ALOX12 P18054 4/20 0.60
LMNA P02545 4/20 0.60
MAPT P10636 3/20 0.60
MEN1 O00255 3/20 0.60
KMT2A Q03164 3/20 0.60
SMN1; SMN2 Q16637 4/20 0.59
HPGD P15428 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
MAPK1 P28482 1/20 0.55
PTPN7 P35236 1/20 0.55
DUSP3 P51452 1/20 0.55
PTPN5 P54829 1/20 0.55
PTPN11 Q06124 1/20 0.55
TAAR1 Q96RJ0 1/20 0.55
CYP1A2 P05177 2/20 0.52
CYP3A4 P08684 2/20 0.52
CYP2D6 P10635 2/20 0.52
CYP2C19 P33261 2/20 0.52
NPC1 O15118 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680329 0.90 ALDH1A1 (0.50) ALDH1A1ALOX12LMNAMAPTMEN1
SCHEMBL4351301 0.88 SMN1; SMN2 (0.60) ALDH1A1ALOX12LMNAMAPTSMN1; SMN2
SCHEMBL4341271 0.85 NPC1 (0.52) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL4351439 0.81 MEN1 (0.72) ALDH1A1ALOX12LMNAMAPTMEN1
SCHEMBL4349372 0.79 ALDH1A1 (0.55) ALDH1A1LMNAMAPTKMT2ASMN1; SMN2
SCHEMBL4358544 0.79 HTT (0.48) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL4356054 0.78 MAPK1 (0.70) ALDH1A1ALOX12LMNAMAPTMEN1
SCHEMBL4350883 0.78 MEN1 (0.59) ALDH1A1ALOX12LMNAMAPTMEN1
SCHEMBL6958878 0.77 MAPT (0.83) ALDH1A1ALOX12LMNAMAPTMEN1
SCHEMBL4346975 0.77 RAB9A (0.68) ALDH1A1ALOX12LMNAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF JERINI AG (DE) 2011-03-17 US claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP claimed
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors JERINI AG (DE) 2007-03-08 US claimed
CN-1701061-A Novel compounds for inhibiting rotamase enzymes and uses thereof JERINI AG (DE) 2005-11-23 CN claimed
EP-2100876-A2 New compounds for the inhibition of rotamases and use thereof Jerini AG (DE) 2009-09-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110065760-A1 COMPOUNDS FOR THE INHIBITION OF ROTAMASES AND USE THEREOF NR1I3, NR1D1, NR1D2 ALDH1A1 2565/4885ALOX12 1546/4885LMNA 3160/4885
US-20070054904-A1 Phenol derivatives and their use as rotamase inhibitors NR1I3, NR1D1, NR1D2 ALDH1A1 2767/4885ALOX12 1994/4885LMNA 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.